Proposal of the Election Committee Regarding Members of The Board etc. for Vitrolife AB (publ)

Regulatory News:

The Election Committee of Vitrolife, which was appointed in accordance with the resolution of the Annual General Meeting, consists of: Henrik Blomquist, representing Bure Equity AB Johan Ståhl, representing Lannebo Fonder Martin Lewin, representing Eccenovo AB Patrik Tigerschiöld, Chairman of the Board

The Board proposes re-election of the Board members Patrik Tigerschiöld, Madeleine Olsson-Eriksson, Fredrik Mattsson, Maris Hartmanis and Tord Lendau and election of the new Board member Barbro Fridén (Director of the Children’s Division at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital). The Board member Semmy Rülf has declined re-election. It is proposed that Patrik Tigerschiöld be re-elected as Chairman of the Board. It is proposed that Board fees of SEK 700,000 be paid, with SEK 200,000 to the Chairman of the Board and SEK 100,000 kronor to each of the other members of the Board. The proposal means that the total Board fee is unchanged from the previous year. Furthermore, the Election Committee proposes that a new Election Committee be set up for the Annual General Meeting of 2011. It is proposed that the Election Committee is appointed in the same way as previously, whereby the Chairman of the Board contacts the three largest registered shareholders or otherwise known owners at the end of the third quarter of 2010 and asks them to appoint one member each. The three members who are appointed and the Chairman of the Board constitute the Election Committee. The Election Committee appoints a Chairman internally.

________________________________________________________________________________________________________________________________

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 170 employees and the company’s products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan. Production facilities are located in Sweden and USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

_________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Tuesday March 23, 2010 at 17:15 pm CET.

This is a translation of the Swedish version of the notice. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://www.cisionwire.com